What This Means for Our Practice Seven additional Phase 3 trials are expected in 2026, evaluating retatrutide across obesity, type 2 diabetes, sleep apnea, chronic low back pain, and MASLD
We offer Semaglutide a GLP-1 receptor agonistas part of our evidence-based approach to weight management and metabolic health
All research protocols were reviewed and approved by the Amgen Institutional Animal Care and Use Committee (Thousand Oaks, CA), Toronto Centre for Phenogenomics at Mount Sinai Hospital (Toronto, Canada) and Danish Animal Experimentation Council (Hrsholm, Denmark)
However, it is only a matter of time before we will have more definitive answers
Troy Watsons Guide to Starting Semaglutide GLP-1 in the First Week at Set Point Medical Troy Watsons approach to starting semaglutide GLP-1 at Set Point Medical is designed to ensure each patient gets the best possible start on their weight loss journey
At 2 years, 83.3% individuals who were adherent taking their semaglutide 2.4 mg once weekly (Wegovy) maintained greater than 5% weight loss